Hypothesis

With advancing age, enterochromaffin (EC) cells accumulate mitochondrial-derived reactive oxygen species (ROS) that selectively oxidize cysteine residues in the pore region of Piezo2 mechanosensitive channels. This oxidative modification lowers Piezo2 open probability, blunting the Ca2+ influx needed for action potential‑dependent serotonin (5‑HT) release. Consequently, mechanosensitive 5‑HT output falls despite unchanged EC cell number or TPH1 expression, contributing to slowed colonic transit and the shift toward a pro‑inflammatory microbiome observed in aged individuals.

Mechanistic Rationale

1. EC cells are redox‑sensitive – They express NADPH oxidases and mitochondrial complexes that generate ROS in response to microbial metabolites [1]. Aging is known to increase mitochondrial ROS production in many intestinal epithelial cell types, leading to oxidative stress‑induced protein modifications.
2. Piezo2 activity depends on cysteine redox state – Structural studies show that several extracellular cysteines regulate channel gating; oxidation can stabilize the closed conformation [2]. No study has yet examined whether EC‑cell Piezo2 is similarly regulated.
3. Mechanosensitive 5‑HT release drives motility and microbiome homeostasis – Piezo2‑dependent Ca2+ spikes trigger vesicle fusion and 5‑HT excretion, which stimulates peristalsis and shapes bacterial communities via immune modulation [3]. A decline in this signal would reduce fluid secretion and favor anaerobic, mucin‑degrading taxa that thrive in slower transit.
4. TPH1 expression may be preserved – Early‑life stress models show EC hyperplasia and elevated 5‑HT without changes in synthesis enzymes, suggesting that release machinery, not synthesis, is the plasticity node [3]. Therefore, aging likely targets the release step rather than serotonin production.

Testable Predictions

• Prediction 1: Isolated colonic EC cells from aged (≥20 mo) mice will exhibit reduced Piezo2‑mediated Ca2+ transients in response to mechanical stretch compared with young (3 mo) cells, while baseline intracellular Ca2+ remains unchanged.
• Prediction 2: Biotin‑switch assays will reveal increased cysteine oxidation on Piezo2 from aged EC cells; treatment with the mitochondria‑targeted antioxidant MitoTEMPO ex vivo will restore mechanosensitive Ca2+ responses.
• Prediction 3: In vivo, aged mice fed MitoTEMPO will show rescued colonic transit times (measured by carmine red assay) and normalized fecal 5‑HT levels, accompanied by a shift in microbiome composition toward higher SCFA‑producing taxa (e.g., Lactobacillus, Bifidobacterium).
• Prediction 4: Genetic rescue via EC‑cell–specific expression of a cysteine‑to‑serine mutant Piezo2 (oxidation‑resistant) in aged mice will normalize 5‑HT release and ameliorate constipation without altering mitochondrial ROS levels.

Experimental Approach

1. Cell preparation – Use fluorescently labeled EC cells (TPH1‑Cre;Rosa26‑tdTomato) isolated from young and aged mice.
2. Mechanostimulation – Apply controlled hypotonic swelling or microfluidic stretch while monitoring GCaMP6f Ca2+ signals.
3. Redox profiling – Perform biotin‑switch followed by Western blot for Piezo2; quantify oxidized vs total peptide via targeted mass spectrometry.
4. Pharmacologic intervention – Treat isolated cells or colonic segments with MitoTEMPO (500 nM) or vehicle; assess Ca2+ dynamics and 5‑HT release (ELISA).
5. In vivo validation – Administer MitoTEMPO in drinking water (1 mg/mL) to aged mice for 4 weeks; collect transit data, fecal 5‑HT, and 16S rRNA microbiome profiles.
6. Genetic test – Cross TPH1‑Cre mice with a Cre‑dependent Piezo2‑C→S knock‑in line; repeat aging studies.

Potential Impact

Confirming that oxidative modification of Piezo2 underlies age‑related EC dysfunction would reveal a druggable node linking mitochondrial health, mechanotransduction, and gut‑brain signaling. It would shift the therapeutic focus from global serotonin supplementation to preserving mechanosensor fidelity, offering a precise strategy to mitigate constipation and microbiome‑driven inflammation in the elderly.

References [1] https://pubmed.ncbi.nlm.nih.gov/40812684/ [2] https://www.pnas.org/doi/10.1073/pnas.1804938115 [3] https://www.frontiersin.org/journals/cellular-neuroscience/articles/10.3389/fncel.2022.837166/full